Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 27, 2022 at 06:01 pm IST
Share
Hunan Hansen Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 890.33 million compared to CNY 739.97 million a year ago. Revenue was CNY 891.84 million compared to CNY 741.24 million a year ago. Net income was CNY 134.85 million compared to CNY 106.15 million a year ago. Basic earnings per share from continuing operations was CNY 0.268 compared to CNY 0.2109 a year ago. Diluted earnings per share from continuing operations was CNY 0.268 compared to CNY 0.2109 a year ago.
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Companyâs main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.
HUNAN HANSEN PHARMACEUTICAL CO., LTD. 
